诺氟沙星（MK - 0366，AM - 715）及其他药物对胃肠道病原体的体外抗菌活性。
In vitro antibacterial activity of norfloxacin (MK-0366, AM-715) and other agents against gastrointestinal tract pathogens.
作者信息
Shungu D L, Weinberg E, Gadebusch H H
出版信息
Antimicrob Agents Chemother. 1983 Jan;23(1):86-90. doi: 10.1128/AAC.23.1.86.
Abstract
A comparison was made of the in vitro activities of norfloxacin and of nine other orally administered antibacterial agents against 180 clinical isolates representing the bacterial species most frequently implicated in infections of the gastrointestinal tract in humans. The 90% minimal inhibitory concentrations showed norfloxacin to be 4, 15, 4, 17, 17, 17, and 33 times more active than the next best compound tested against Campylobacter fetus subsp. jejuni, Escherichia coli, Salmonella spp., Shigella spp., Vibrio cholerae, Vibrio parahaemolyticus, and Yersinia enterocolitica, respectively, with an overall 90% minimal inhibitory concentration of less than or equal to 0.5 micrograms/ml. Norfloxacin was least active against Clostridium difficile (90% minimal inhibitory concentration, 128 micrograms/ml). These results should encourage further evaluation of norfloxacin as a potential chemotherapeutic agent in the treatment of enteric bacterial infections for which antibiotic therapy is indicated.
摘要
对诺氟沙星和其他九种口服抗菌剂的体外活性进行了比较，它们作用于180株临床分离菌，这些分离菌代表了人类胃肠道感染中最常涉及的细菌种类。90%最小抑菌浓度表明，诺氟沙星对胎儿弯曲菌空肠亚种、大肠杆菌、沙门氏菌属、志贺氏菌属、霍乱弧菌、副溶血性弧菌和小肠结肠炎耶尔森菌的活性分别比下一个最佳测试化合物高4、15、4、17、17、17和33倍，总体90%最小抑菌浓度小于或等于0.5微克/毫升。诺氟沙星对艰难梭菌的活性最低（90%最小抑菌浓度为128微克/毫升）。这些结果应促使人们进一步评估诺氟沙星作为一种潜在化疗药物治疗需要抗生素治疗的肠道细菌感染的可能性。
相似文献
1
In vitro antibacterial activity of norfloxacin (MK-0366, AM-715) and other agents against gastrointestinal tract pathogens.诺氟沙星（MK - 0366，AM - 715）及其他药物对胃肠道病原体的体外抗菌活性。
Antimicrob Agents Chemother. 1983 Jan;23(1):86-90. doi: 10.1128/AAC.23.1.86.
2
In vitro activity of norfloxacin and other antibacterial agents against gastro-intestinal pathogens isolated in Sweden.
APMIS. 1990 Feb;98(2):150-5. doi: 10.1111/j.1699-0463.1990.tb01015.x.
3
Norfloxacin: in vitro activity compared with that of seven other antibacterial agents against urinary tract pathogens.诺氟沙星：与其他七种抗菌剂相比，对尿路病原体的体外活性。
Acta Pathol Microbiol Immunol Scand B. 1984 Apr;92(2):101-6. doi: 10.1111/j.1699-0463.1984.tb02802.x.
4
Antibacterial efficacy of norfloxacin, trimethoprim-sulfamethoxazole, and gentamicin in experimentally-infected normal and streptozotocin-induced diabetic mice.诺氟沙星、甲氧苄啶-磺胺甲恶唑和庆大霉素在实验感染的正常小鼠和链脲佐菌素诱导的糖尿病小鼠中的抗菌疗效。
Methods Find Exp Clin Pharmacol. 1984 Dec;6(12):731-5.
5
Comparison of the antibacterial activity of norfloxacin (MK 0366, AM 715), a new organic acid, with that of other orally absorbed chemotherapeutic agents.新型有机酸诺氟沙星（MK 0366，AM 715）与其他口服吸收的化疗药物抗菌活性的比较。
Infection. 1982 Jan;10(1):41-4. doi: 10.1007/BF01640837.
6
In vitro antibacterial activity of norfloxacin and other agents against ocular pathogens.诺氟沙星及其他药物对眼部病原体的体外抗菌活性。
Chemotherapy. 1985;31(2):112-8. doi: 10.1159/000238322.
7
Comparative trial of norfloxacin and trimethoprim-sulfamethoxazole in the treatment of women with localized, acute, symptomatic urinary tract infections and antimicrobial effect on periurethral and fecal microflora.诺氟沙星与甲氧苄啶-磺胺甲恶唑治疗女性局部急性症状性尿路感染的对比试验及其对尿道周围和粪便微生物群的抗菌作用
Antimicrob Agents Chemother. 1984 Oct;26(4):481-4. doi: 10.1128/AAC.26.4.481.
8
The comparative in vitro activity of twelve 4-quinolone antimicrobials against enteric pathogens.十二种4-喹诺酮类抗菌药物对肠道病原体的体外活性比较
Drugs Exp Clin Res. 1985;11(4):253-7.
9
The antimicrobial spectrum of norfloxacin.诺氟沙星的抗菌谱。
J Antimicrob Chemother. 1984 May;13 Suppl B:25-31. doi: 10.1093/jac/13.suppl_b.25.
10
In vitro activity of MK-0366 against clinical urinary pathogens including gentamicin-resistant Pseudomonas aeruginosa.MK-0366对包括耐庆大霉素铜绿假单胞菌在内的临床尿路病原体的体外活性。
Antimicrob Agents Chemother. 1982 Apr;21(4):670-2. doi: 10.1128/AAC.21.4.670.
引用本文的文献
1
Epidemiology and Control of Strawberry Bacterial Angular Leaf Spot Disease Caused by Xanthomonas fragariae.草莓细菌性角斑病（由草莓黄单胞菌引起）的流行病学与防治
Plant Pathol J. 2016 Aug;32(4):290-9. doi: 10.5423/PPJ.OA.01.2016.0007. Epub 2016 Aug 1.
2
Sequence analysis of the gyrA and parC homologues of a wild-type strain of Vibrio parahaemolyticus and its fluoroquinolone-resistant mutants.副溶血性弧菌野生型菌株及其氟喹诺酮抗性突变体的gyrA和parC同源物的序列分析。
Antimicrob Agents Chemother. 1999 May;43(5):1156-62. doi: 10.1128/AAC.43.5.1156.
3
Comparative in vitro activity of ciprofloxacin against Campylobacter spp. and other bacterial enteric pathogens.环丙沙星对弯曲杆菌属及其他肠道病原菌的体外活性比较
Antimicrob Agents Chemother. 1984 Apr;25(4):504-6. doi: 10.1128/AAC.25.4.504.
4
In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent.新型羧基喹啉抗菌剂环丙沙星的体外活性
Antimicrob Agents Chemother. 1984 Mar;25(3):331-5. doi: 10.1128/AAC.25.3.331.
5
Comparison of the in vitro activity of ciprofloxacin (Bay o 9867) and norfloxacin against gastrointestinal tract pathogens.
Eur J Clin Microbiol. 1984 Aug;3(4):367. doi: 10.1007/BF01977497.
6
Recovery of norfloxacin in feces after administration of a single oral dose to human volunteers.给人类志愿者单次口服给药后粪便中诺氟沙星的回收率。
Antimicrob Agents Chemother. 1984 Jul;26(1):110-1. doi: 10.1128/AAC.26.1.110.
7
Antibacterial activity of norfloxacin in the gastrointestinal tracts of rats.诺氟沙星在大鼠胃肠道中的抗菌活性。
Antimicrob Agents Chemother. 1983 Oct;24(4):560-3. doi: 10.1128/AAC.24.4.560.
8
Multicenter evaluation of the proposed quality control limits and interpretive zone standards for in vitro susceptibility testing with norfloxacin.对诺氟沙星体外药敏试验建议的质量控制限度和解释范围标准的多中心评估。
J Clin Microbiol. 1983 Oct;18(4):988-91. doi: 10.1128/jcm.18.4.988-991.1983.
9
Three-year prospective study of intestinal pathogens in Madrid, Spain.西班牙马德里肠道病原体的三年前瞻性研究。
J Clin Microbiol. 1984 Aug;20(2):290-2. doi: 10.1128/jcm.20.2.290-292.1984.
10
In vitro susceptibility of pathogenic Vibrio species to norfloxacin and six other antimicrobial agents.致病性弧菌属对诺氟沙星及其他六种抗菌剂的体外敏感性
Antimicrob Agents Chemother. 1985 Sep;28(3):442-5. doi: 10.1128/AAC.28.3.442.
本文引用的文献
1
Diarrhoea: causes and specific treatment.腹泻：病因及特效治疗
Drugs. 1981 Jan;21(1):62-8. doi: 10.2165/00003495-198121010-00004.
2
Susceptibility testing to trimethoprim alone and combined with sulphonamides.单独及与磺胺类药物联合使用时对甲氧苄啶的药敏试验。
Chemotherapy. 1980;26(6):418-26. doi: 10.1159/000237937.
3
Treatment of experimentally induced enterotoxigenic Escherichia coli diarrhea with trimethoprim, trimethoprim-sulfamethoxazole, or placebo.用甲氧苄啶、甲氧苄啶 - 磺胺甲恶唑或安慰剂治疗实验性诱导的产肠毒素大肠杆菌腹泻。
Rev Infect Dis. 1982 Mar-Apr;4(2):540-5. doi: 10.1093/clinids/4.2.540.
4
Emergence of high-level trimethoprim resistance in fecal Escherichia coli during oral administration of trimethoprim or trimethoprim--sulfamethoxazole.口服甲氧苄啶或甲氧苄啶-磺胺甲恶唑期间粪便中大肠杆菌出现高水平甲氧苄啶耐药性。
N Engl J Med. 1982 Jan 21;306(3):130-5. doi: 10.1056/NEJM198201213060302.
5
Successful treatment of an institutional outbreak of shigellosis.志贺氏菌病机构性暴发的成功治疗
Clin Pediatr (Phila). 1981 Feb;20(2):127-31. doi: 10.1177/000992288102000207.
6
Infection prevention in granulocytopenic patients by selective decontamination of the digestive tract.通过消化道选择性去污对粒细胞缺乏症患者进行感染预防。
Eur J Cancer (1965). 1980 Jun;16(6):859-69. doi: 10.1016/0014-2964(80)90140-1.
7
Trimethoprim: mechanisms of action, antimicrobial activity, bacterial resistance, pharmacokinetics, adverse reactions, and therapeutic indications.
Pharmacotherapy. 1981 Jul-Aug;1(1):14-20. doi: 10.1002/j.1875-9114.1981.tb03548.x.
8
The screening of four aminoglycosides in the selective decontamination of the digestive tract in mice.小鼠消化道选择性去污中四种氨基糖苷类药物的筛选。
Infection. 1982 Jan;10(1):35-40. doi: 10.1007/BF01640836.
9
Comparison of the antibacterial activity of norfloxacin (MK 0366, AM 715), a new organic acid, with that of other orally absorbed chemotherapeutic agents.新型有机酸诺氟沙星（MK 0366，AM 715）与其他口服吸收的化疗药物抗菌活性的比较。
Infection. 1982 Jan;10(1):41-4. doi: 10.1007/BF01640837.
10
Comparative in vitro activity of Mk-0366 and other selected oral antimicrobial agents against Neisseria gonorrhoeae.Mk-0366与其他选定口服抗菌剂对淋病奈瑟菌的体外活性比较
Antimicrob Agents Chemother. 1981 Aug;20(2):265-6. doi: 10.1128/AAC.20.2.265.
Zotero 插件